Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

195 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment.
Viswanathan L, Bachman E, Tian S, Ahluwalia N, Zhang Y, Bernstein HS, Panorchan P. Viswanathan L, et al. Among authors: ahluwalia n. Eur J Drug Metab Pharmacokinet. 2022 Nov;47(6):817-825. doi: 10.1007/s13318-022-00791-8. Epub 2022 Aug 29. Eur J Drug Metab Pharmacokinet. 2022. PMID: 36036885 Free PMC article. Clinical Trial.
A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation.
Davies JC, Sermet-Gaudelus I, Naehrlich L, Harris RS, Campbell D, Ahluwalia N, Short C, Haseltine E, Panorchan P, Saunders C, Owen CA, Wainwright CE; VX16-661-115 Investigator Group. Davies JC, et al. Among authors: ahluwalia n. J Cyst Fibros. 2021 Jan;20(1):68-77. doi: 10.1016/j.jcf.2020.07.023. Epub 2020 Sep 21. J Cyst Fibros. 2021. PMID: 32967799 Free article. Clinical Trial.
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele.
Zemanick ET, Taylor-Cousar JL, Davies J, Gibson RL, Mall MA, McKone EF, McNally P, Ramsey BW, Rayment JH, Rowe SM, Tullis E, Ahluwalia N, Chu C, Ho T, Moskowitz SM, Noel S, Tian S, Waltz D, Weinstock TG, Xuan F, Wainwright CE, McColley SA. Zemanick ET, et al. Among authors: ahluwalia n. Am J Respir Crit Care Med. 2021 Jun 15;203(12):1522-1532. doi: 10.1164/rccm.202102-0509OC. Am J Respir Crit Care Med. 2021. PMID: 33734030 Free PMC article. Clinical Trial.
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study.
Mall MA, Brugha R, Gartner S, Legg J, Moeller A, Mondejar-Lopez P, Prais D, Pressler T, Ratjen F, Reix P, Robinson PD, Selvadurai H, Stehling F, Ahluwalia N, Arteaga-Solis E, Bruinsma BG, Jennings M, Moskowitz SM, Noel S, Tian S, Weinstock TG, Wu P, Wainwright CE, Davies JC. Mall MA, et al. Among authors: ahluwalia n. Am J Respir Crit Care Med. 2022 Dec 1;206(11):1361-1369. doi: 10.1164/rccm.202202-0392OC. Am J Respir Crit Care Med. 2022. PMID: 35816621 Free PMC article. Clinical Trial.
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Sutharsan S, McKone EF, Downey DG, Duckers J, MacGregor G, Tullis E, Van Braeckel E, Wainwright CE, Watson D, Ahluwalia N, Bruinsma BG, Harris C, Lam AP, Lou Y, Moskowitz SM, Tian S, Yuan J, Waltz D, Mall MA; VX18-445-109 study group. Sutharsan S, et al. Among authors: ahluwalia n. Lancet Respir Med. 2022 Mar;10(3):267-277. doi: 10.1016/S2213-2600(21)00454-9. Epub 2021 Dec 20. Lancet Respir Med. 2022. PMID: 34942085 Clinical Trial.
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS; VX17-445-103 Trial Group. Heijerman HGM, et al. Among authors: ahluwalia n. Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31. Lancet. 2019. PMID: 31679946 Free PMC article. Clinical Trial.
Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes.
Barry PJ, Mall MA, Álvarez A, Colombo C, de Winter-de Groot KM, Fajac I, McBennett KA, McKone EF, Ramsey BW, Sutharsan S, Taylor-Cousar JL, Tullis E, Ahluwalia N, Jun LS, Moskowitz SM, Prieto-Centurion V, Tian S, Waltz D, Xuan F, Zhang Y, Rowe SM, Polineni D; VX18-445-104 Study Group. Barry PJ, et al. Among authors: ahluwalia n. N Engl J Med. 2021 Aug 26;385(9):815-825. doi: 10.1056/NEJMoa2100665. N Engl J Med. 2021. PMID: 34437784 Free PMC article. Clinical Trial.
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis.
Walker S, Flume P, McNamara J, Solomon M, Chilvers M, Chmiel J, Harris RS, Haseltine E, Stiles D, Li C, Ahluwalia N, Zhou H, Owen CA, Sawicki G; VX15-661-113 Investigator Group. Walker S, et al. Among authors: ahluwalia n. J Cyst Fibros. 2019 Sep;18(5):708-713. doi: 10.1016/j.jcf.2019.06.009. Epub 2019 Jun 26. J Cyst Fibros. 2019. PMID: 31253540 Free article. Clinical Trial.
A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation.
McKone EF, DiMango EA, Sutharsan S, Barto TL, Campbell D, Ahluwalia N, Higgins M, Owen CA, Tullis E. McKone EF, et al. Among authors: ahluwalia n. J Cyst Fibros. 2021 Mar;20(2):234-242. doi: 10.1016/j.jcf.2020.11.003. Epub 2020 Dec 16. J Cyst Fibros. 2021. PMID: 33339768 Free article. Clinical Trial.
A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant.
Sawicki GS, Chilvers M, McNamara J, Naehrlich L, Saunders C, Sermet-Gaudelus I, Wainwright CE, Ahluwalia N, Campbell D, Harris RS, Paz-Diaz H, Shih JL, Davies JC. Sawicki GS, et al. Among authors: ahluwalia n. J Cyst Fibros. 2022 Jul;21(4):675-683. doi: 10.1016/j.jcf.2022.02.003. Epub 2022 Feb 18. J Cyst Fibros. 2022. PMID: 35190292 Free article. Clinical Trial.
Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.
Schwarz C, Sutharsan S, Epaud R, Klingsberg RC, Fischer R, Rowe SM, Audhya PK, Ahluwalia N, You X, Ferro TJ, Duncan ME, Bruinsma BG. Schwarz C, et al. Among authors: ahluwalia n. J Cyst Fibros. 2021 Mar;20(2):228-233. doi: 10.1016/j.jcf.2020.06.001. Epub 2020 Jun 23. J Cyst Fibros. 2021. PMID: 32586736 Free PMC article. Clinical Trial.
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE; VX14-661-110 study group. Flume PA, et al. Among authors: ahluwalia n. Lancet Respir Med. 2021 Jul;9(7):733-746. doi: 10.1016/S2213-2600(20)30510-5. Epub 2021 Feb 10. Lancet Respir Med. 2021. PMID: 33581080
Anatomy, Abdomen and Pelvis: Celiac Trunk.
Ahluwalia N, Nassereddin A, Arbor TC, Futterman B. Ahluwalia N, et al. 2024 Jan 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2024 Jan 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 29083567 Free Books & Documents.
The BLISTER Score: A Novel, Externally Validated Tool for Predicting Cardiac Implantable Electronic Device Infections, and Its Cost-Utility Implications for Antimicrobial Envelope Use.
Maclean E, Mahtani K, Honarbakhsh S, Butcher C, Ahluwalia N, Dennis ASC, Creta A, Finlay M, Elliott M, Mehta V, Wijesuriya N, Shaikh O, Zaw Y, Ogbedeh C, Gautam V, Lambiase PD, Schilling RJ, Earley MJ, Moore P, Muthumala A, Sporton SCE, Hunter RJ, Rinaldi CA, Behar J, Martin C, Monkhouse C, Chow A. Maclean E, et al. Among authors: ahluwalia n. Circ Arrhythm Electrophysiol. 2024 Mar;17(3):e012446. doi: 10.1161/CIRCEP.123.012446. Epub 2024 Jan 22. Circ Arrhythm Electrophysiol. 2024. PMID: 38258308 Free PMC article.
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study.
Daines CL, Tullis E, Costa S, Linnemann RW, Mall MA, McKone EF, Polineni D, Quon BS, Ringshausen FC, Rowe SM, Selvadurai H, Taylor-Cousar JL, Withers NJ, Ahluwalia N, Moskowitz SM, Prieto-Centurion V, Tan YV, Tian S, Weinstock T, Xuan F, Zhang Y, Ramsey B, Griese M; VX17-445-105 Study Group. Daines CL, et al. Among authors: ahluwalia n. Eur Respir J. 2023 Dec 7;62(6):2202029. doi: 10.1183/13993003.02029-2022. Print 2023 Dec. Eur Respir J. 2023. PMID: 37945033 Free PMC article. Clinical Trial.
ECGI targeted ablation for persistent AF not responding to pulmonary vein isolation: Results of a two-staged strategy (TARGET AF2).
Dhillon G, Honarbakhsh S, Abbas H, Waddingham P, Dennis AS, Ahluwalia N, Finlay M, Sohaib A, Welch S, Daw H, Sporton S, Chow A, Earley MJ, Lambiase PD, Hunter RJ. Dhillon G, et al. Among authors: ahluwalia n. Heart Rhythm O2. 2023 Aug 31;4(10):609-617. doi: 10.1016/j.hroo.2023.08.004. eCollection 2023 Oct. Heart Rhythm O2. 2023. PMID: 37936670 Free PMC article.
Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events.
Ramsey B, Correll CU, DeMaso DR, McKone E, Tullis E, Taylor-Cousar JL, Chu C, Volkova N, Ahluwalia N, Waltz D, Tian S, Mall MA. Ramsey B, et al. Among authors: ahluwalia n. Am J Respir Crit Care Med. 2024 Feb 1;209(3):299-306. doi: 10.1164/rccm.202308-1525OC. Am J Respir Crit Care Med. 2024. PMID: 37890129 Free PMC article. Review.
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical Trial.
Wainwright C, McColley SA, McNally P, Powers M, Ratjen F, Rayment JH, Retsch-Bogart G, Roesch E, Ahluwalia N, Chin A, Chu C, Lu M, Menon P, Waltz D, Weinstock T, Zelazoski L, Davies JC. Wainwright C, et al. Among authors: ahluwalia n. Am J Respir Crit Care Med. 2023 Jul 1;208(1):68-78. doi: 10.1164/rccm.202301-0021OC. Am J Respir Crit Care Med. 2023. PMID: 37154609
A worldwide survey on incidence, management, and prognosis of oesophageal fistula formation following atrial fibrillation catheter ablation: the POTTER-AF study.
Tilz RR, Schmidt V, Pürerfellner H, Maury P, Chun KRJU, Martinek M, Sohns C, Schmidt B, Mandel F, Gandjbakhch E, Laredo M, Gunawardene MA, Willems S, Beiert T, Borlich M, Iden L, Füting A, Spittler R, Gaspar T, Richter S, Schade A, Kuniss M, Neumann T, Francke A, Wunderlich C, Shin DI, Meininghaus DG, Foresti M, Bonsels M, Reek D, Wiegand U, Bauer A, Metzner A, Eckardt L, Popescu SȘ, Krahnefeld O, Sticherling C, Kühne M, Nguyen DQ, Roten L, Saguner AM, Linz D, van der Voort P, Mulder BA, Vijgen J, Almorad A, Guenancia C, Fauchier L, Boveda S, Greef Y, Da Costa A, Jais P, Derval N, Milhem A, Jesel L, Garcia R, Poty H, Khoueiry Z, Seitz J, Laborderie J, Mechulan A, Brigadeau F, Zhao A, Saludas Y, Piot O, Ahluwalia N, Martin C, Chen J, Antolic B, Leventopoulos G, Özcan EE, Yorgun H, Cay S, Yalin K, Botros MS, Mahmoud AT, Jędrzejczyk-Patej E, Inaba O, Okumura K, Ejima K, Khakpour H, Boyle N, Catanzaro JN, Reddy V, Mohanty S, Natale A, Blessberger H, Yang B, Stevens I, Sommer P, Veltmann C, Steven D, Vogler J, Kuck KH, Merino JL, Keelani A, Heeger CH. Tilz RR, et al. Among authors: ahluwalia n. Eur Heart J. 2023 Jul 14;44(27):2458-2469. doi: 10.1093/eurheartj/ehad250. Eur Heart J. 2023. PMID: 37062040 Free PMC article.
Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele.
Goralski JL, Hoppe JE, Mall MA, McColley SA, McKone E, Ramsey B, Rayment JH, Robinson P, Stehling F, Taylor-Cousar JL, Tullis E, Ahluwalia N, Chin A, Chu C, Lu M, Niu T, Weinstock T, Ratjen F, Rosenfeld M. Goralski JL, et al. Among authors: ahluwalia n. Am J Respir Crit Care Med. 2023 Jul 1;208(1):59-67. doi: 10.1164/rccm.202301-0084OC. Am J Respir Crit Care Med. 2023. PMID: 36921081 Free PMC article.
Catheter ablation of atrial fibrillation with a multi-electrode radiofrequency balloon; first and early two centre experience in Europe.
Kanthasamy V, Breitenstein A, Schilling R, Hofer D, Tiongco B, Ang R, Hunter R, Earley M, Ahsan S, Mangiafico V, Honarbakhsh S, Ahluwalia N, Maclean E, Creta A, Finlay M. Kanthasamy V, et al. Among authors: ahluwalia n. J Cardiovasc Electrophysiol. 2023 Jun;34(6):1350-1359. doi: 10.1111/jce.15799. Epub 2023 Jan 26. J Cardiovasc Electrophysiol. 2023. PMID: 36598422 Free article.
Driver characteristics associated with structurally and electrically remodeled atria in persistent atrial fibrillation.
Dhillon GS, Honarbakhsh S, Graham A, Ahluwalia N, Abbas H, Welch S, Daw H, Chow A, Earley MJ, Providencia R, Schilling RJ, Lambiase PD, Hunter RJ. Dhillon GS, et al. Among authors: ahluwalia n. Heart Rhythm O2. 2022 Sep 28;3(6Part A):631-638. doi: 10.1016/j.hroo.2022.09.016. eCollection 2022 Dec. Heart Rhythm O2. 2022. PMID: 36589910 Free PMC article.
Harnessing Country Experiences for Health Benefit Package Design: Evidence-Informed Deliberative Processes and Experiences From the Joint Learning Network Comment on "Evidence-Informed Deliberative Processes for Health Benefit Package Design - Part II: A Practical Guide".
Nagpal S, Ahluwalia N, Hashiguchi LO, McGee K, Lutalo M. Nagpal S, et al. Among authors: ahluwalia n. Int J Health Policy Manag. 2023;12:7856. doi: 10.34172/ijhpm.2023.7856. Epub 2023 Oct 28. Int J Health Policy Manag. 2023. PMID: 38618786 Free PMC article.
Awareness of the MyPlate Plan: United States, 2017-March 2020.
Wambogo E, Ansai N, Wang CY, Terry A, Fryar CD, Ahluwalia N, Ogden CL. Wambogo E, et al. Among authors: ahluwalia n. Natl Health Stat Report. 2022 Nov;(178):1-14. Natl Health Stat Report. 2022. PMID: 36454172 Free article.
Long-term outcomes following catheter ablation versus medical therapy in patients with persistent atrial fibrillation and heart failure with reduced ejection fraction.
Zakeri R, Ahluwalia N, Tindale A, Omar F, Packer M, Khan H, Baker V, Honarbakhsh S, Earley MJ, Sporton S, Schilling RJ, Jones D, Markides V, Hunter RJ, Wong T; ARC-HF and CAMTAF Investigators. Zakeri R, et al. Among authors: ahluwalia n. Eur J Heart Fail. 2023 Jan;25(1):77-86. doi: 10.1002/ejhf.2714. Epub 2022 Nov 1. Eur J Heart Fail. 2023. PMID: 36221809 Free article. Clinical Trial.
Frequency of Eating in the US Population: A Narrative Review of the 2020 Dietary Guidelines Advisory Committee Report.
Bailey RL, Leidy HJ, Mattes RD, Heymsfield SB, Boushey CJ, Ahluwalia N, Cowan AE, Pannucci T, Moshfegh AJ, Goldman JD, Rhodes DG, Stoody EE, de Jesus J, Casavale KO. Bailey RL, et al. Among authors: ahluwalia n. Curr Dev Nutr. 2022 Aug 29;6(9):nzac132. doi: 10.1093/cdn/nzac132. eCollection 2022 Sep. Curr Dev Nutr. 2022. PMID: 36110105 Free PMC article.
Perspective: Human Milk Composition and Related Data for National Health and Nutrition Monitoring and Related Research.
Ahuja JKC, Casavale KO, Li Y, Hopperton KE, Chakrabarti S, Hines EP, Brooks SPJ, Bondy GS, MacFarlane AJ, Weiler HA, Wu X, Borghese MM, Ahluwalia N, Cheung W, Vargas AJ, Arteaga S, Lombo T, Fisher MM, Hayward D, Pehrsson PR. Ahuja JKC, et al. Among authors: ahluwalia n. Adv Nutr. 2022 Dec 22;13(6):2098-2114. doi: 10.1093/advances/nmac099. Adv Nutr. 2022. PMID: 36084013 Free PMC article.
Unmasking Hansen's disease through an ophthalmologist's eye.
Ahluwalia NS, Choudhary P, Shakya R, Revankar A. Ahluwalia NS, et al. Indian J Ophthalmol. 2022 Jul;70(7):2671-2673. doi: 10.4103/ijo.IJO_2157_21. Indian J Ophthalmol. 2022. PMID: 35791198 Free PMC article. No abstract available.
Transseptal puncture for left atrial ablation: Risk factors for cardiac tamponade and a proposed causative classification system.
Maclean E, Mahtani K, Roelas M, Vyas R, Butcher C, Ahluwalia N, Honarbakhsh S, Creta A, Finlay M, Chow A, Earley M, Sporton S, Lowe M, Sawhney V, Ezzat V, Ahsan S, Khan F, Dhinoja M, Lambiase P, Schilling R, Hunter R, Segal O. Maclean E, et al. Among authors: ahluwalia n. J Cardiovasc Electrophysiol. 2022 Aug;33(8):1747-1755. doi: 10.1111/jce.15590. Epub 2022 Jun 17. J Cardiovasc Electrophysiol. 2022. PMID: 35671359 Free PMC article.
Contemporary Practice and Optimising Referral Pathways for Implantable Cardiac Monitoring for Atrial Fibrillation after Cryptogenic Stroke.
Ahluwalia N, Graham A, Honarbakhsh S, Tarkas T, Martin S, Monkhouse C, Finlay M, Earley MJ, Icart R, Spooner O, Chandratheva A, Schilling RJ. Ahluwalia N, et al. J Stroke Cerebrovasc Dis. 2022 Jul;31(7):106474. doi: 10.1016/j.jstrokecerebrovasdis.2022.106474. Epub 2022 May 8. J Stroke Cerebrovasc Dis. 2022. PMID: 35544977
Erratum for Long-term outcomes of index cryoballoon ablation or point-by-point radiofrequency ablation in patients with atrial fibrillation and systolic heart failure. J Cardiovasc Electrophysiol. 2021;32:941-948.
Prabhu S, Ahluwalia N, Tyebally SM, Dennis ASC, Malomo SO, Abiodun AT, Tyrlis A, Dhillon G, Segan L, Graham A, Honarbakhsh S, Sawhney V, Sporton S, Lowe M, Finlay M, Earley MJ, Lambiase P, Schilling RJ, Hunter RJ. Prabhu S, et al. Among authors: ahluwalia n. J Cardiovasc Electrophysiol. 2022 Mar;33(3):567. doi: 10.1111/jce.15312. Epub 2022 Feb 15. J Cardiovasc Electrophysiol. 2022. PMID: 35166413 No abstract available.
Noninvasive electrocardiographic imaging-guided targeting of drivers of persistent atrial fibrillation: The TARGET-AF1 trial.
Honarbakhsh S, Dhillon G, Abbass H, Waddingham PH, Dennis A, Ahluwalia N, Welch S, Daw H, Sporton S, Chow A, Earley MJ, Lambiase PD, Hunter RJ. Honarbakhsh S, et al. Among authors: ahluwalia n. Heart Rhythm. 2022 Jun;19(6):875-884. doi: 10.1016/j.hrthm.2022.01.042. Epub 2022 Feb 5. Heart Rhythm. 2022. PMID: 35134548 Clinical Trial.
Lessons in cognitive unloading, skills mixing, flattened hierarchy and organisational agility from the Nightingale Hospital London during the first wave of the SARS-CoV-2 pandemic.
Collins GB, Ahluwalia N, Arrol L, Forrest N, McGlennan A, O'Brien B, Proudfoot A, Trainer M, Schilling R, Sullivan E, Westwood M, Wragg A, Knight C. Collins GB, et al. Among authors: ahluwalia n. BMJ Open Qual. 2021 Jul;10(3):e001415. doi: 10.1136/bmjoq-2021-001415. BMJ Open Qual. 2021. PMID: 34301730 Free PMC article. Review. No abstract available.
Impact of adenosine on mechanisms sustaining persistent atrial fibrillation: Analysis of contact electrograms and non-invasive ECGI mapping data.
Dhillon GS, Ahluwalia N, Honarbakhsh S, Graham A, Creta A, Abbass H, Chow A, Earley MJ, Lambiase PD, Schilling RJ, Hunter RJ. Dhillon GS, et al. Among authors: ahluwalia n. PLoS One. 2021 Mar 25;16(3):e0248951. doi: 10.1371/journal.pone.0248951. eCollection 2021. PLoS One. 2021. PMID: 33765054 Free PMC article. Clinical Trial.
Post-acute COVID-19 syndrome.
Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR, Nordvig AS, Shalev D, Sehrawat TS, Ahluwalia N, Bikdeli B, Dietz D, Der-Nigoghossian C, Liyanage-Don N, Rosner GF, Bernstein EJ, Mohan S, Beckley AA, Seres DS, Choueiri TK, Uriel N, Ausiello JC, Accili D, Freedberg DE, Baldwin M, Schwartz A, Brodie D, Garcia CK, Elkind MSV, Connors JM, Bilezikian JP, Landry DW, Wan EY. Nalbandian A, et al. Among authors: ahluwalia n. Nat Med. 2021 Apr;27(4):601-615. doi: 10.1038/s41591-021-01283-z. Epub 2021 Mar 22. Nat Med. 2021. PMID: 33753937 Free PMC article. Review.
Long-term outcomes of index cryoballoon ablation or point-by-point radiofrequency ablation in patients with atrial fibrillation and systolic heart failure.
Prabhu S, Ahluwalia N, Tyebally SM, Dennis ASC, Malomo SO, Abiodun AT, Tyrlis A, Dhillon G, Segan L, Graham A, Honarbakhsh S, Sawhney V, Sporton S, Lowe M, Finlay M, Earley MJ, Lambiase P, Schilling RJ, Hunter RJ. Prabhu S, et al. Among authors: ahluwalia n. J Cardiovasc Electrophysiol. 2021 Apr;32(4):941-948. doi: 10.1111/jce.14923. Epub 2021 Feb 10. J Cardiovasc Electrophysiol. 2021. PMID: 33527562
Extrapulmonary manifestations of COVID-19.
Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, Bikdeli B, Ahluwalia N, Ausiello JC, Wan EY, Freedberg DE, Kirtane AJ, Parikh SA, Maurer MS, Nordvig AS, Accili D, Bathon JM, Mohan S, Bauer KA, Leon MB, Krumholz HM, Uriel N, Mehra MR, Elkind MSV, Stone GW, Schwartz A, Ho DD, Bilezikian JP, Landry DW. Gupta A, et al. Among authors: ahluwalia n. Nat Med. 2020 Jul;26(7):1017-1032. doi: 10.1038/s41591-020-0968-3. Epub 2020 Jul 10. Nat Med. 2020. PMID: 32651579 Review.
T-Cell Receptor Excision Circles in Newborns with Congenital Heart Disease.
Davey BT, Elder RW, Cloutier MM, Bennett N, Lee JH, Wang Z, Manning A, Doan T, Griffiths M, Perez M, Ahluwalia N, Toro-Salazar OH. Davey BT, et al. Among authors: ahluwalia n. J Pediatr. 2019 Oct;213:96-102.e2. doi: 10.1016/j.jpeds.2019.05.061. Epub 2019 Jul 2. J Pediatr. 2019. PMID: 31277900
Corrigendum: ADAM10-mediated ephrin-B2 shedding promotes myofibroblast activation and organ fibrosis.
Lagares D, Ghassemi-Kakroodi P, Tremblay C, Santos A, Probst CK, Franklin A, Santos DM, Grasberger P, Ahluwalia N, Montesi SB, Shea BS, Black KE, Knipe R, Blati M, Baron M, Wu B, Fahmi H, Gandhi R, Pardo A, Selman M, Wu J, Pelletier JP, Martel-Pelletier J, Tager AM, Kapoor M. Lagares D, et al. Among authors: ahluwalia n. Nat Med. 2017 Dec 7;23(12):1499. doi: 10.1038/nm1217-1499b. Nat Med. 2017. PMID: 29216045
ADAM10-mediated ephrin-B2 shedding promotes myofibroblast activation and organ fibrosis.
Lagares D, Ghassemi-Kakroodi P, Tremblay C, Santos A, Probst CK, Franklin A, Santos DM, Grasberger P, Ahluwalia N, Montesi SB, Shea BS, Black KE, Knipe R, Blati M, Baron M, Wu B, Fahmi H, Gandhi R, Pardo A, Selman M, Wu J, Pelletier JP, Martel-Pelletier J, Tager AM, Kapoor M. Lagares D, et al. Among authors: ahluwalia n. Nat Med. 2017 Dec;23(12):1405-1415. doi: 10.1038/nm.4419. Epub 2017 Oct 23. Nat Med. 2017. PMID: 29058717 Free PMC article.
195 results